Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Use of a probabilistic PBPK/PD model to calculate Data Derived Extrapolation Factors for chlorpyrifos.

Poet TS, Timchalk C, Bartels MJ, Smith JN, McDougal R, Juberg DR, Price PS.

Regul Toxicol Pharmacol. 2017 Jun;86:59-73. doi: 10.1016/j.yrtph.2017.02.014. Epub 2017 Feb 24.

PMID:
28238854
2.

Using physiologically based pharmacokinetic modeling and benchmark dose methods to derive an occupational exposure limit for N-methylpyrrolidone.

Poet TS, Schlosser PM, Rodriguez CE, Parod RJ, Rodwell DE, Kirman CR.

Regul Toxicol Pharmacol. 2016 Apr;76:102-12. doi: 10.1016/j.yrtph.2015.12.020. Epub 2016 Jan 8.

3.

Methyl isobutyl ketone exposure-related increases in specific measures of α2u-globulin (α2u) nephropathy in male rats along with in vitro evidence of reversible protein binding.

Borghoff SJ, Poet TS, Green S, Davis J, Hughes B, Mensing T, Sarang SS, Lynch AM, Hard GC.

Toxicology. 2015 Jul 3;333:1-13. doi: 10.1016/j.tox.2015.02.003. Epub 2015 Mar 19.

PMID:
25797582
4.

Chlorpyrifos PBPK/PD model for multiple routes of exposure.

Poet TS, Timchalk C, Hotchkiss JA, Bartels MJ.

Xenobiotica. 2014 Oct;44(10):868-81. doi: 10.3109/00498254.2014.918295. Epub 2014 May 19.

PMID:
24839995
5.

A human life-stage physiologically based pharmacokinetic and pharmacodynamic model for chlorpyrifos: development and validation.

Smith JN, Hinderliter PM, Timchalk C, Bartels MJ, Poet TS.

Regul Toxicol Pharmacol. 2014 Aug;69(3):580-97. doi: 10.1016/j.yrtph.2013.10.005. Epub 2013 Nov 4.

PMID:
24200834
6.

Impact of repeated nicotine and alcohol coexposure on in vitro and in vivo chlorpyrifos dosimetry and cholinesterase inhibition.

Lee S, Poet TS, Smith JN, Hjerpe AL, Gunawan R, Timchalk C.

J Toxicol Environ Health A. 2011;74(20):1334-50. doi: 10.1080/15287394.2011.567958.

PMID:
21899407
7.

Development of a source-to-outcome model for dietary exposures to insecticide residues: an example using chlorpyrifos.

Hinderliter PM, Price PS, Bartels MJ, Timchalk C, Poet TS.

Regul Toxicol Pharmacol. 2011 Oct;61(1):82-92. doi: 10.1016/j.yrtph.2011.06.004. Epub 2011 Jun 22.

PMID:
21722690
8.

Application of a source-to-outcome model for the assessment of health impacts from dietary exposures to insecticide residues.

Price PS, Schnelle KD, Cleveland CB, Bartels MJ, Hinderliter PM, Timchalk C, Poet TS.

Regul Toxicol Pharmacol. 2011 Oct;61(1):23-31. doi: 10.1016/j.yrtph.2011.05.009. Epub 2011 May 30.

PMID:
21651950
9.

In vitro age-dependent enzymatic metabolism of chlorpyrifos and chlorpyrifos-oxon in human hepatic microsomes and chlorpyrifos-oxon in plasma.

Smith JN, Timchalk C, Bartels MJ, Poet TS.

Drug Metab Dispos. 2011 Aug;39(8):1353-62. doi: 10.1124/dmd.111.038745. Epub 2011 Apr 26.

PMID:
21521795
10.

Hydroquinone PBPK model refinement and application to dermal exposure.

Poet TS, Carlton BD, Deyo JA, Hinderliter PM.

Food Chem Toxicol. 2010 Nov;48(11):3085-92. doi: 10.1016/j.fct.2010.08.002. Epub 2010 Aug 6.

PMID:
20692312
11.

Effect of in vivo nicotine exposure on chlorpyrifos pharmacokinetics and pharmacodynamics in rats.

Lee S, Poet TS, Smith JN, Busby-Hjerpe AL, Timchalk C.

Chem Biol Interact. 2010 Mar 30;184(3):449-57. doi: 10.1016/j.cbi.2010.01.024. Epub 2010 Jan 25.

PMID:
20097188
12.

Comparative pharmacokinetics of chlorpyrifos versus its major metabolites following oral administration in the rat.

Busby-Hjerpe AL, Campbell JA, Smith JN, Lee S, Poet TS, Barr DB, Timchalk C.

Toxicology. 2010 Jan 31;268(1-2):55-63. doi: 10.1016/j.tox.2009.11.022. Epub 2009 Dec 4.

PMID:
19963030
13.

Quantitative risk analysis for N-methyl pyrrolidone using physiologically based pharmacokinetic and benchmark dose modeling.

Poet TS, Kirman CR, Bader M, van Thriel C, Gargas ML, Hinderliter PM.

Toxicol Sci. 2010 Feb;113(2):468-82. doi: 10.1093/toxsci/kfp264. Epub 2009 Oct 29.

PMID:
19875680
14.

In vitro glutathione conjugation of methyl iodide in rat, rabbit, and human blood and tissues.

Poet TS, Wu H, Corley RA, Thrall KD.

Inhal Toxicol. 2009 May;21(6):524-30. doi: 10.1080/08958370802598203.

PMID:
19519152
15.

Comparative chlorpyrifos pharmacokinetics via multiple routes of exposure and vehicles of administration in the adult rat.

Smith JN, Campbell JA, Busby-Hjerpe AL, Lee S, Poet TS, Barr DB, Timchalk C.

Toxicology. 2009 Jun 30;261(1-2):47-58. doi: 10.1016/j.tox.2009.04.041. Epub 2009 May 3.

PMID:
19397948
16.

The effect of plasma lipids on the pharmacokinetics of chlorpyrifos and the impact on interpretation of blood biomonitoring data.

Lowe ER, Poet TS, Rick DL, Marty MS, Mattsson JL, Timchalk C, Bartels MJ.

Toxicol Sci. 2009 Apr;108(2):258-72. doi: 10.1093/toxsci/kfp034. Epub 2009 Feb 17.

PMID:
19223661
17.

Effects of nicotine exposure on in vitro metabolism of chlorpyrifos in male Sprague-Dawley rats.

Lee S, Busby AL, Timchalk C, Poet TS.

J Toxicol Environ Health A. 2009;72(2):74-82. doi: 10.1080/15287390802477288.

PMID:
19034796
18.
19.

In vitro measurements of metabolism for application in pharmacokinetic modeling.

Lipscomb JC, Poet TS.

Pharmacol Ther. 2008 Apr;118(1):82-103. doi: 10.1016/j.pharmthera.2008.01.006. Epub 2008 Feb 15. Review.

PMID:
18374419
20.

Physiologically based pharmacokinetic modeling of 1,4-Dioxane in rats, mice, and humans.

Sweeney LM, Thrall KD, Poet TS, Corley RA, Weber TJ, Locey BJ, Clarkson J, Sager S, Gargas ML.

Toxicol Sci. 2008 Jan;101(1):32-50. Epub 2007 Sep 25.

PMID:
17897969
21.
22.

Age-related brain cholinesterase inhibition kinetics following in vitro incubation with chlorpyrifos-oxon and diazinon-oxon.

Kousba AA, Poet TS, Timchalk C.

Toxicol Sci. 2007 Jan;95(1):147-55. Epub 2006 Oct 3.

PMID:
17018647
23.
24.

Pharmacokinetic and pharmacodynamic interaction for a binary mixture of chlorpyrifos and diazinon in the rat.

Timchalk C, Poet TS, Hinman MN, Busby AL, Kousba AA.

Toxicol Appl Pharmacol. 2005 May 15;205(1):31-42.

PMID:
15885262
25.

Determination of age and gender differences in biochemical processes affecting the disposition of 2-butoxyethanol and its metabolites in mice and rats to improve PBPK modeling.

Corley RA, Grant DM, Farris E, Weitz KK, Soelberg JJ, Thrall KD, Poet TS.

Toxicol Lett. 2005 Mar 28;156(1):127-61.

PMID:
15705493
26.

Derivation of a human equivalent concentration for n-butanol using a physiologically based pharmacokinetic model for n-butyl acetate and metabolites n-butanol and n-butyric acid.

Teeguarden JG, Deisinger PJ, Poet TS, English JC, Faber WD, Barton HA, Corley RA, Clewell HJ 3rd.

Toxicol Sci. 2005 May;85(1):429-46. Epub 2005 Feb 9.

PMID:
15703268
27.

Physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus pesticide diazinon.

Poet TS, Kousba AA, Dennison SL, Timchalk C.

Neurotoxicology. 2004 Dec;25(6):1013-30.

PMID:
15474619
28.

Metabolic rate constants for hydroquinone in F344 rat and human liver isolated hepatocytes: application to a PBPK model.

Poet TS, Wu H, English JC, Corley RA.

Toxicol Sci. 2004 Nov;82(1):9-25. Epub 2004 Jul 22.

PMID:
15272136
29.

Noninvasive biomonitoring approaches to determine dosimetry and risk following acute chemical exposure: analysis of lead or organophosphate insecticide in saliva.

Timchalk C, Poet TS, Kousba AA, Campbell JA, Lin Y.

J Toxicol Environ Health A. 2004 Apr 23-May 28;67(8-10):635-50. Review.

PMID:
15192859
30.

Comparison of chlorpyrifos-oxon and paraoxon acetylcholinesterase inhibition dynamics: potential role of a peripheral binding site.

Kousba AA, Sultatos LG, Poet TS, Timchalk C.

Toxicol Sci. 2004 Aug;80(2):239-48. Epub 2004 May 12.

PMID:
15141101
31.
32.

In vitro rat hepatic and intestinal metabolism of the organophosphate pesticides chlorpyrifos and diazinon.

Poet TS, Wu H, Kousba AA, Timchalk C.

Toxicol Sci. 2003 Apr;72(2):193-200. Epub 2003 Mar 7.

PMID:
12655035
33.

Mode of action and pharmacokinetic studies of 2-butoxyethanol in the mouse with an emphasis on forestomach dosimetry.

Poet TS, Soelberg JJ, Weitz KK, Mast TJ, Miller RA, Thrall BD, Corley RA.

Toxicol Sci. 2003 Feb;71(2):176-89.

PMID:
12563103
35.

Skin absorption and human risk assessment.

Poet TS, McDougal JN.

Chem Biol Interact. 2002 Apr 20;140(1):19-34. Review.

PMID:
12044558
36.

PBPK modeling of the percutaneous absorption of perchloroethylene from a soil matrix in rats and humans.

Poet TS, Weitz KK, Gies RA, Edwards JA, Thrall KD, Corley RA, Tanojo H, Hui X, Maibach HI, Wester RC.

Toxicol Sci. 2002 May;67(1):17-31.

PMID:
11961212
37.
38.

Assessing dermal absorption.

Poet TS.

Toxicol Sci. 2000 Nov;58(1):1-2. Review.

PMID:
11053533
39.

Comparative metabolism of carbon tetrachloride in rats, mice, and hamsters using gas uptake and PBPK modeling.

Thrall KD, Vucelick ME, Gies RA, Zangar RC, Weitz KK, Poet TS, Springer DL, Grant DM, Benson JM.

J Toxicol Environ Health A. 2000 Aug 25;60(8):531-48.

PMID:
10983521
40.

Assessment of the percutaneous absorption of trichloroethylene in rats and humans using MS/MS real-time breath analysis and physiologically based pharmacokinetic modeling.

Poet TS, Corley RA, Thrall KD, Edwards JA, Tanojo H, Weitz KK, Hui X, Maibach HI, Wester RC.

Toxicol Sci. 2000 Jul;56(1):61-72.

PMID:
10869454
41.
42.

A real-time in-vivo method for studying the percutaneous absorption of volatile chemicals.

Thrall KD, Poet TS, Corley RA, Tanojo H, Edwards JA, Weitz KK, Hui X, Maibach HI, Wester RC.

Int J Occup Environ Health. 2000 Apr-Jun;6(2):96-103. Review.

PMID:
10828137
43.

Utility of real time breath analysis and physiologically based pharmacokinetic modeling to determine the percutaneous absorption of methyl chloroform in rats and humans.

Poet TS, Thrall KD, Corley RA, Hui X, Edwards JA, Weitz KK, Maibach HI, Wester RC.

Toxicol Sci. 2000 Mar;54(1):42-51.

PMID:
10746930
44.

Evaluation of the in vivo interaction of methyl tert-butyl ether with alpha2u-globulin in male F-344 rats.

Prescott-Mathews JS, Poet TS, Borghoff SJ.

Toxicol Appl Pharmacol. 1999 May 15;157(1):60-7.

PMID:
10329508
45.

Pharmacokinetics of tertiary butyl alcohol in male and female Fischer 344 rats.

Poet TS, Valentine JL, Borghoff SJ.

Toxicol Lett. 1997 Aug 22;92(3):179-86.

PMID:
9334828
46.
47.

Participation of cytochromes P4502B and P4503A in cocaine toxicity in rat hepatocytes.

Poet TS, McQueen CA, Halpert JR.

Drug Metab Dispos. 1996 Jan;24(1):74-80.

PMID:
8825193
48.
49.

Inactivation of cytochromes P450 2B protects against cocaine-mediated toxicity in rat liver slices.

Poet TS, Brendel K, Halpert JR.

Toxicol Appl Pharmacol. 1994 May;126(1):26-32.

PMID:
8184429
50.

Cocaine metabolite (benzoylecgonine) in hair and urine of drug users.

Martinez F, Poet TS, Pillai R, Erickson J, Estrada AL, Watson RR.

J Anal Toxicol. 1993 May-Jun;17(3):138-42.

PMID:
8336486

Supplemental Content

Support Center